Merck & Co. (6MK.DE) Stock Price

€72.6 1.7%

Sign up
to add to portfolio

AI Score

Hold

  • Alternative

    5

  • Fundamental

    8

  • Technical

    5

Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.

Sign up to get access to more historical data and insights on Merck & Co., AI stock picks, stock alerts and much more.

Sign up

6MK.DE AI Stock Analysis

AI stock analysis for 6MK.DE is missing at the moment.

Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Merck & Co. (6MK.DE) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.

Sign up and become a member to get access to AI stock analysis.

Sign up

Merck & Co. (6MK.DE) Price Prediction

Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Merck & Co. (6MK.DE), currently trading at €72.6, will... Sign up to access price prediction.

Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.

About 6MK.DE

LSE

  • Merck & Co.

  • Symbol

    6MK.DE

  • Market

    XETRA

  • Industry

    Drug Manufacturers - General

  • Market Cap

    181.3B

Similar Stocks

PFE.F Pfizer Inc.
PFE.F		 €21.56
0.8%
5
AMG.DE Amgen Inc.
AMG.DE		 €254
1%
6
ZEG.DE AstraZeneca PLC
ZEG.DE		 €136
1.3%
7
PFE.DE Pfizer Inc.
PFE.DE		 €21.58
0.8%
5
IDP.DE Biogen Inc.
IDP.DE		 €118.6
1.4%
7

News

Avidicure Launches with $50 Million in Seed Financing to Develop New Multifunctional Antibody Modality to Treat Cancer

Avidicure Launches with $50 Million in Seed Financing to Develop New Multifunctional Antibody Modality to Treat Cancer
April 24, 2025. GlobeNewswire
Merck's Q1 sales down 2% to $15.5 billion

Merck's Q1 sales down 2% to $15.5 billion
April 24, 2025. Biztoc.com
Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery

Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery
April 23, 2025. GlobeNewswire
Merck & Co., Inc. (MRK): Among Prem Watsa’s Stock Picks With Highest Potential

Merck & Co., Inc. (MRK): Among Prem Watsa’s Stock Picks With Highest Potential
April 22, 2025. Yahoo Entertainment

6MK.DE Alternative Data

Web Traffic

Merck & Co. receives an estimated 738202 monthly visitors to merck.com.

  • Web Traffic

    738202

  • Change from Previous Month

    4.3%

  • 3 Month Change

    4.2%

  • YoY Change

    4.2%

Twitter Followers

Merck & Co. has 217,390 Twitter Followers on its main Twitter (also known as X) account, which is up by 0.1% over the last month.

  • Twitter Followers

    217390

  • Daily Change

    0%

  • 1 Month Change

    0.1%

  • 3 Month Change

    0.3%

  • YoY Change

    0.3%

Facebook Engagement

Merck & Co. has engaged 5,130 users via their Facebook Page over the last 7 days.

  • Facebook Engagement

    5130

  • Daily Change

    5.4%

  • 1 Month Change

    3%

  • 3 Month Change

    39.3%

  • YoY Change

    39.3%

Instagram Followers

Merck & Co. has 0 Instagram Followers on its main Instagram account.

  • Instagram Followers

    0

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

  • YoY Change

    0%

Youtube Subscribers

Merck & Co. has 3,960 subscribers on its main Youtube channel.

  • Youtube Subscribers

    3960

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0.8%

  • YoY Change

    0.8%

Job Postings

Merck & Co. has an estimated 140 open job postings, which is down -8.5% over the last month.

  • Job Postings

    140

  • Daily Change

    2.8%

  • 1 Month Change

    8.5%

  • 3 Month Change

    21.3%

  • YoY Change

    21.3%

Reddit Mentions

Merck & Co. has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.

  • Reddit Mentions

    0

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

LinkedIn Followers

2,462,113 are following Merck & Co. on LinkedIn, up by 1.4% over the last month.

  • LinkedIn Followers

    2462113

  • Daily Change

    1.4%

  • 1 Month Change

    1.4%

  • 3 Month Change

    2.9%

  • YoY Change

    2.9%

LinkedIn Employees

According to LinkedIn, Merck & Co. has 44,090 employees, up by 0.3% over the last month.

  • LinkedIn Employees

    44090

  • Daily Change

    0.3%

  • 1 Month Change

    0.3%

  • 3 Month Change

    2.1%

  • YoY Change

    2.1%

Business Outlook

According to employee reviews, the business outlook among employees at Merck & Co. is 76 out of 100 (bullish).

  • Business Outlook

    76

  • Change from Previous Month

    1.3%

  • 3 Month Change

    2.6%

  • YoY Change

    2.6%

News Mentions

Merck & Co. was mentioned 17 times in the news yesterday.

  • News Mentions

    17

  • Daily Change

    6.3%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

  • YoY Change

    0%

6MK.DE Financials

6MK.DE Key Metrics

  • Total Revenue

    $15.5B

  • Net Income

    $5.1B

  • Earnings per Share

    $2.02

  • Free cash flow

    $1.2B

  • EBITDA

    $7.3B

  • EBITDA Ratio

    0.471054

  • Total Assets

    $115.1B

6MK.DE 2-year Revenue & Income
6MK.DE 2-year Free Cash Flow

6MK.DE Technicals

6MK.DE SMA
6MK.DE RSI

FAQ

What's the current price of Merck & Co. (6MK.DE) Stock?
The price of an Merck & Co. (6MK.DE) share is €72.6.

What's the market cap of Merck & Co.?
The current market cap of Merck & Co. is 181.3B.

Should I buy or sell 6MK.DE?
Merck & Co. shows several positive indicators, but they aren’t strong enough to warrant a buy recommendation. At its current price, Merck & Co. is better viewed as a hold or accumulate position while waiting for further developments.

Is Merck & Co. a good investment?
The current analysis of Merck & Co.'s fundamentals, technical aspects, and alternative data insights indicates a neutral outlook on the stock. While there are promising elements in Merck & Co.'s portfolio, the presence of equal risks and opportunities suggests that it might not drive significant gains or losses at this moment.

Is now a good time to buy Merck & Co. (6MK.DE) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, the outlook for Merck & Co. stock is currently neutral, suggesting a cautious approach might be wise.

What are some stocks similar to Merck & Co. (6MK.DE) that investors often compare it to?
Merck & Co. (6MK.DE) is often compared to similar stocks such as Pfizer Inc., Amgen Inc., AstraZeneca PLC, Pfizer Inc. and Biogen Inc..

What is the forecast for Merck & Co.'s stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Merck & Co.'s stock price to be around €73.62 in 2026. Starting from the current price of €72.6, this represents a 1.4% change in price, indicating a neutral outlook for the stock.

How to buy Merck & Co. (6MK.DE) Stock?
Merck & Co. stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Merck & Co. shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.